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ABSTRACT 
A 26-residue peptide BimBH3 binds indiscriminately to multiple oncogenic Bcl2 proteins that regulate 
apoptosis of cancer cells. Specific inhibition of the BimBH3-Bcl2A1 protein-protein interaction was 
obtained in vitro and in cancer cells by shortening the peptide to 14 residues, inserting two cyclization 
constraints to stabilize a water-stable alpha helix, and incorporating an N-terminal acrylamide 
electrophile for selective covalent bonding to Bcl2A1. Mass spectrometry of trypsin-digested bands on 
electrophoresis gels established covalent bonding of an electrophilic helix to just one of the three 
cysteines in Bcl2A1, the one (Cys55) at the BimBH3-Bcl2A1 protein-protein interaction interface. 
Optimizing the helix-inducing constraints and the sequence subsequently enabled electrophile removal 
without loss of inhibitor potency. The bicyclic helical peptides were potent, cell permeable, plasma-
stable, dual inhibitors of Bcl2A1 and Mcl-1 with high selectivity over other Bcl2 proteins. One bicyclic 
peptide was shown to inhibit the interaction between a pro-apoptotic protein (Bim) and either 
endogenous Bcl2A1 or Mcl-1, to induce apoptosis of SKMel28 human melanoma cells, and to sensitize 
them for enhanced cell death by the anticancer drug etoposide. These approaches look promising for 
chemically silencing intracellular proteins.  
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INTRODUCTION 
 Tumor cells develop the capacity during oncogenesis to evade regulatory apoptosis by 
overexpressing prosurvival proteins or downregulating pro-apoptotic signalling pathways. These 
measures also enable cancer cells to survive DNA-damaging cytotoxic drugs. Apoptosis is 
regulated by a complex network of proteins, including anti-apoptotic (e.g. Bcl-2, Bcl-xL, Bcl-w, 
Mcl-1, Bcl2A1) and pro-apoptotic Bcl2 family proteins.1 The expression and importance of each 
anti-apoptotic protein varies with cancer cell lineage and tumor stage, and may change during 
chemotherapy.1 Therefore, inhibiting one or more of these proteins has the potential to induce 
apoptosis in different types and stages of cancer.1  
 Pro-apoptotic proteins present their α-helical BH3 domain to a conserved hydrophobic 
cleft within anti-apoptotic proteins, and this has guided rational design of inhibitors of Bcl2 
proteins.1 These inhibitors have been either peptides modeled after BH3 domains or synthetic 
small organic molecules, with some validated examples undergoing clinical trials, including 
ABT-737 and navitoclax (targeting Bcl-2/Bcl-xL/Bcl-w), obatoclax (pan-Bcl2 inhibitor) and 
venetoclax, a recent FDA-approved drug targeting Bcl-2 in chronic lymphocytic leukemia.2  
 Mcl-1 is a related Bcl2 family protein overexpressed in a variety of human cancers3 
whereas Bcl2A1 (abbreviated A1) is more often upregulated in melanoma, leukemia and 
lymphoma.4 Both A1 and Mcl-1 have important roles in melanoma progression.5-8 Their 
simultaneous knockdown using siRNA caused death of melanoma cells, while healthy cells were 
unaffected.6 Moreover, melanoma resistance to Braf or MEK inhibitors correlated with A1 and 
Mcl-1 upregulation and was attenuated by neutralizing with siRNA.5-8 Therefore, new drugs that 
selectively inhibit both A1 and Mcl-1 proteins might be very promising. Only a few compounds 
are known to exclusively act on Mcl-1 in cells,9-11 with a newly discovered small molecule 
showing promise in clinical studies,10 while selective A1 modulators are not yet well 
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developed.12,13 Compounds that inhibit all Bcl-2 family proteins are known, but recent clinical 
trials showed that Bcl-xL inhibition can be toxic to platelets so more target selectivity is 
required.1b-1d 
   The BH3 domain of pro-apoptotic protein Bim (BimBH3 81-106, Figure 1) binds tightly 
to all anti-apoptotic Bcl2 proteins.14 Several studies have used either computational modelling, 
single point mutation or phage display library screening to identify possible ways to obtain 
BimBH3 analogues with specificity over different Bcl2 family proteins. 12,15-19 When searching 
for A1/Mcl-1 exclusive peptide epitopes, a 26-mer peptide BimS2A (L62A/F69A) was shown to 
be selective for Mcl-1,17 while a 23-mer BimBH3 peptide derivative encompassing 4 mutations 
was found to bind selectively to A1.12 Such linear peptides are prone to rapid metabolic 
degradation and low cell membrane permeability, preventing their clinical use. To overcome this 
limitation, a hydrocarbon crosslinker was inserted previously into BimBH3 (generating 21-mer 
pan-Bcl2 inhibitor BimSAHBA, Figure 1), in a chemical approach known as stapling, that 
stabilized the α-helical conformation of the peptide and allowed its cell uptake by cancer cells 
inducing apoptosis.20 With five residues removed from the N-terminus of BimBH3, BimSAHBA 
nevertheless binds promiscuously to all anti-apoptotic Bcl-2 proteins. To our knowledge, there 
are no reports describing cell permeable Bim-peptide variants selective for A1 and Mcl-1, but a 
modified stapled BimBH3 peptide was recently shown to bind exclusively to Mcl-1 and to 
induce death of Mcl-1 dependent cells .21  
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Figure 1. BimBH3 (pink) interacts with all anti-apoptotic Bcl2 proteins, including A1 (green, 
PDB 2vm6) and Mcl-1 (gray, PDB 2nl9) by presenting four conserved hydrophobic residues 
(H1-H4) on one helical face to the BH3 groove. When equipped with a helical-inducing 
hydrocarbon crosslinker (BimSAHBA), BimBH3 can enter into cancer cells and trigger 
apoptosis.20 When the native Trp2 in BimSAHBA (blue) is modified with an electrophilic residue 
(red) to form peptide 1 (X= Dap-N-acrylamide), exclusive covalent bonding to a uniquely 
positioned cysteine in A1 (Cys55) takes place, without interaction with other exposed cysteines 
on the surface of A1 or other Bcl2 proteins (cysteines in yellow).22  
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 We22,23 and others24 recently reported a strategy for potently inhibiting Bcl2A1 by 
covalently bonding BimBH3 peptides to a distinctive cysteine (Cys 55) located in the BimBH3-
binding site in A1 (Figure 1). This cysteine is not present in the BH3 binding site of other anti-
apoptotic Bcl2 proteins.22,24 Our approach utilized an acrylamide as an electrophilic warhead 
which was incorporated at position 2 in BimSAHBA (e.g. peptide 1 in Figure 1) and was found to 
selectively and covalently bond in vitro through Michael addition to Cys55 in A1,22 but not to 
two other cysteines located on the exposed surface of A1. This afforded a cell-penetrating 
stapled peptide that covalently targeted A1 in living cells.22,24a Although affinity to A1 was 
enhanced in this way, peptide 1 can still interact non-covalently with other Bcl2 proteins, 
including Bcl-xL.20 Here we describe further development of helical peptide ligands for A1, 
using electrophilic analogues for structure-activity optimization, culminating in a potent inhibitor 
of A1 and Mcl-1 that does not bind to other Bcl2 family proteins.  
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RESULTS AND DISCUSSION 
 
Design of bicyclic helical peptides. Although interacting residues are distributed all 
along the BimBH3 peptide sequence, molecular dynamics and mutagenesis studies suggested to 
us that its C-terminal region may be less important for binding to A1 and Mcl-1 than to other 
Bcl2 proteins.15-18 Therefore we sought to downsize BimSAHBA, which indiscriminately binds to 
all Bcl2 proteins, in order to investigate whether shorter peptides could bind selectively to A1 or 
Mcl-1. These peptides must also penetrate cells to inhibit Bcl2 function in mitochondria. Flow 
cytometry is normally used to measure cell uptake, but requires tagging helical peptides with 
bulky hydrophobic fluorescent probes25 that can themselves artificially promote cell uptake. To 
remove this possibility, we instead equipped our peptides with a small acrylamide warhead at 
position 2 (Figure 2). This permitted covalent bonding to A1 in cells, readily detected using 
western blot as previously observed with peptide 1.22 In this way, we could verify whether new 
peptides enter cells, escape endosomes and interact with endogenous Bcl2 proteins located in the 
mitochondria.  
 Among shorter peptides that we synthesized was peptide 2, with the last seven C-terminal 
residues from 1 removed to produce a 14-residue peptide featuring a hydrophobic helix-inducing 
constraint and an acrylamide electrophile at position 2 (Figure 2). Using circular dichroism 
spectroscopy, we found that α-helicity in aqueous media was significantly reduced upon 
truncating 1 (74%) to 2 (47%), consistent with depletion of helix-favoring residues (e.g. Ala16, 
Ala19, Arg20, Arg21). To increase α-helicity, we incorporated a second (i, i + 4) sidechain to 
sidechain crosslink at different positions (not shown), eventually settling on a crosslink between 
residues 1 and 5 as being optimal (Figure 2). A second macrocycle-forming hydrocarbon 
crosslink in 3 resulted in higher α-helicity than 2 in water (containing 20% acetonitrile for 
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solubility). Next we varied the two crosslinks (3-6, Figure 2) featuring hydrocarbon and/or 
lactam bridges. Incorporating a second cycle significantly increased α-helicity for the 14-mer 
peptides, with two hydrocarbon bridges (3) being less helical than one hydrocarbon and one 
lactam (4, 5), while two lactams (6) conferred the most α-helicity. This is consistent with 
published studies on model peptides, where a KD lactam linker induced the greatest peptide α-
helicity in water.26,27 Although less α-helix inducing, highly hydrophobic, hydrocarbon 
crosslinks can be used to promote greater cell permeation in some stapled peptides, including 
BimSAHBA and 1.20,22,25  
 
 
Figure 2. Structure of 14-mer peptides 2-6, derived from 1, featuring one or two crosslinking 
bridges. Right: CD spectra of 1-6 (50 µM) in 20% acetonitrile in water. Percent helicity is in 
parenthesis. X= Dap-N-acrylamide. All peptides are acetylated at the N-terminus and amidated at 
the C-terminus.  
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Synthesis of the bicyclic compounds. Peptides were prepared on solid support using 
standard Fmoc-based solid-phase peptide synthesis (SPPS), followed by on-resin intramolecular 
lactamization of a Lys(Mtt) and Asp(OPip) pair26,27 and, when appropriate, ring-closing 
metathesis between of two S-2-(4′-pentenyl)alanine (S5) residues25 using Grubbs catalyst.28 
Finally, the orthogonal protecting group of Dap2 was removed, allowing incorporation of the 
acrylamide electrophile. Scheme 1 illustrates the synthesis of peptide 5. For other peptides, see 
Figure S1. 
 
 
Scheme 1. Synthesis of bicycle 5. Conditions: a) i. 30% piperidine in DMF, 3 min (2x); ii. 
Fmoc-AA-OH (4 equiv), HCTU (4 equiv), DIPEA (8 equiv) in DMF, 30 min (2x); b) 2% TFA in 
DCM, 10 min (10x); c) PyBOP (4 equiv), DIPEA (8 equiv) in DMF, 6h; d) i. 30% piperidine in 
DMF, 3 min (2x); ii. Ac2O (1 M), DIPEA (0.4 M) in DMF, 5 min (2x); e) 10 mM Grubbs 
catalyst 1st generation in dry DCE, 2h (2x); f) acrylic acid (4 equiv), HATU, (4 equiv), DIPEA (4 
equiv) in DMF, 15 min; g) TFA:TIS:H2O (95:2.5:2.5), 2h. Asterisks indicate use of standard 
protecting groups. 
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Binding to Bcl2 proteins. Next we measured binding to different Bcl2 proteins (Figure 
3) using a fluorescence polarization (FP) assay to observe competition of these new peptides (2-
6) with a fluorescein-labelled Bid ligand (FBid).22 BimBH3 (86-106, BIM) and 1 were compared 
as controls. Because acrylamide-bearing peptides 1-6 bind covalently to A1, the FBid/A1 
inhibitory curves varied over time (Figure S2). The kinetics of the binding are discussed in the 
next section. Here we selected the 2 h incubation time point to compare A1 binding and reported 
the experimental A1-binding parameters as IC50(2h) and Ki(2h) for each peptide 1-6 (Figure 3).  
After 2 h incubation, the bicyclic peptides 3-6 bound more tightly than the monocyclic 2 
or the longer sequences (BIM and 1) to A1 (Figure 3A) and Mcl-1 (Figure 3B), with peptide 5 
being the most effective dual binder to these proteins. These results highlight the advantages in 
target selectivity of stabilizing the N-terminal region with a second helix-inducing constraint. We 
also investigated the effect of truncation and cyclization in the Bim sequence on binding to other 
Bcl2 proteins, using similar competition binding experiments (Figure 3C, Ki for Mcl-1, Bcl-2, 
Bcl-xL and Bcl-w; and Ki(2h) for A1 values in Table S1). As anticipated, C-terminal truncation 
of 1 to form 2-6 led to significant decreases in binding affinity for Bcl-w, Bcl-xL and Bcl-2, 
while still preserving nM affinity for Mcl-1 and A1. 
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Figure 3. Binding of peptides BIM and 1-6 to Bcl2 anti-apoptotic proteins measured by 
competitive FP assays against a Bcl2 protein/FBid complex after 2 h incubation. A, B) Inhibitory 
curves measured after 2 h incubation of peptides with A1/FBid (15/5 nM) (A) or Mcl-1/FBid 
(200/20 nM) (B) complex. IC50 values determined from FP curves are given in adjacent tables; 
for A1, IC50 values are defined as IC50(2h) given the time-dependence of covalent binding; for 
Mcl-1, IC50 values are at equilibrium. C) Comparative Ki values (nM) for binding to all anti-
apoptotic Bcl2 proteins. Ki values below the dotted line were < 1 nM and below assay detection. 
* Ki > 1000 nM. #For covalent binders to A1, Ki values are defined as Ki(2h) given the time-
dependence of covalent binding. 
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Covalent bonding to A1 protein in vitro. Covalent bonding of the acrylamide-peptides 
to A1 gives further insights into binding of the truncated peptides to protein.  The binding is 
time-dependent, as expected for a covalent inhibitor (Figure 4A). We used the second-order rate 
constant kinact/KI to describe the efficiency of covalent bond formation, accounting for both the 
potency of the first step related to affinity (KI) and the maximum rate of covalent bond formation 
(kinact) (Figures 4B and 4C).29 
The best fitting peptides to the binding groove likely position the acrylamide electrophile 
precisely for interaction with Cys55 in A1, facilitating nucleophilic attack and rapid covalent 
bonding. Positioning a lactam bridge near the C-terminus led to faster binding (5 and 6), 
attributed to greater helix induction in this region and better conformational preorganization of 
the peptide for protein binding. The presence of a hydrocarbon linker near the N-terminus 
increased binding, as reflected by a 3-fold higher KI for bicycle 5 in comparison to 6 (Figure 4). 
Overall, bicycle 5 was the most efficient covalent binder. All acrylamide-peptides efficiently 
attached to A1 after 2 h, as assessed by SDS-PAGE electrophoresis (Figures 5A and S3) and 
mass spectrometry (Figures 5B and S4) and only a 1:1 conjugate with A1 was observed, 
consistent with selective covalent bonding to one site only on the protein. The specific site of 
covalent attachment was established for 5 by digesting the protein-peptide conjugate band from 
the gel with trypsin and performing MS/MS analysis (Figure 5C and S5). No peptide herein 
bonded covalently with the other Bcl2 proteins (not shown) consistent with no active site Cys in 
those proteins. Peptides with no warhead such as BIM and bicycle 7, an analogue of 5 with 
acrylamide replaced by a non-electrophilic propionamide isostere (Figure 7A), showed no 
covalent bonding to A1 (Figure 5B).   
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Figure 4. Kinetics of covalent binding of acrylamide-containing peptides 1-6 to A1. A) 
Inhibition of the A1/FBid (15/5 nM) complex changed over time for each peptide concentration 
used ([peptide] = 500, 250, 125, 61.5, 31.2, 15.6, 7.8 and 3.9 nM). The change in polarization 
over time (t) was fitted to the equation: normalized % polarization = 100*(1 - exp(-kobs*t)), to 
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determine kobs, the observed rate of inactivation for each peptide concentration. B) The kobs 
values are then used to determine the parameters kinact and KI by plotting the curve: kobs = 
kinact*[peptide]/(KI + [peptide]). C) Overall, the covalent peptides associate to A1 via a two-step 
mechanism: first peptide binds reversibly to A1 with potency reflected by KI values; then 
irreversibly attaches to A1, with maximum kobs defined as kinact. The kinact/KI rate describes the 
overall efficiency of conversion of free A1 to the covalent A1-peptide complex.29  
 
 
Figure 5. Analysis of covalent bonding of acrylamide-appended peptides to A1 in vitro. A) 
Denaturing SDS-PAGE analysis shows that acrylamide-containing peptides (5 and 1) covalently 
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bond to A1, whereas those without warhead do not (BIM and 7). B) Mass spectrum of the 
A1/peptide 5 conjugate formed after incubating A1 (1 µM, MW: 18786) with 5 (10 µM) for 2 h 
in buffer (pH 7.2), showing the expected molecular weight increment (MW: 20475). No 
evidence of multiple additions of the peptide to the protein was found. C) Mass spectrum 
analysis of the trypsin-digested gel band, containing the A1 protein fragment bearing Cys55 and 
covalently bound peptide 5. The MS/MS fingerprint for m = 2638.30 ([M+3H]3+ = 880.8) 
revealed the expected y ion fragmentation pattern for the A1 derived-sequence 
LDNVNVVSVDTAR and the peptide 5 derived-sequence ELR (Figure S5). Conjugation of ELR 
to other protein fragments was not detected, confirming Cys55 to be the only site of covalent 
peptide attachment.  
 
 
Covalent bonding to A1 protein in cells. To learn whether the peptides could penetrate 
cells and covalently bond to intracellular endogenous A1, they were incubated with live U937 
lymphoma cells for 24 h. Intracellular A1 was analysed by western blot for modified molecular 
weight due to covalent bonding with peptide (Figure 6). Like compound 1 (IC50 ~ 25 µM),22 each 
of the compounds 2-6 did form a covalent adduct consistent with reaction of the electrophile 
with A1. Bicycle 5 (IC50 1-5 µM) was the most effective covalent ligand, while bicycle 6 that 
had similar affinity as 5 for A1 protein in vitro was less effective in U937 cells, presumably 
because of lower cell permeability due to no hydrophobic linker. Bicycle 4, an analogue of 5 
with the positions of the lactam and hydrocarbon bridges swapped around, also exhibited a high 
level of intracellular A1 targeting. Interestingly, the double hydrocarbon-crosslinked peptide 3 
was not as an efficient covalent inhibitor in live cells as the mixed-bicyclic constructs 4 and 5. 
Bicycle 7 with no electrophile showed no covalent bonding to A1.  
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Figure 6. Western blots show concentration-dependent covalent bonding of intracellular A1 to 
peptides with acrylamide (2-6), but not without (7), in live cells.  U937 cells were incubated with 
peptides (24 h, 37 0C) then lysed and analyzed by western blot. 
 
 
 Overall, bicycle 5 was the most efficient binding ligand to A1 and Mcl-1 in vitro and to 
A1 in live cells. Moreover, 5 was a very stable helical scaffold with higher resistance to 
proteolytic and serum degradation than the parent BimSAHBA-derivative 1 (Figures S6 and S7). 
Although BimSAHBA displays enhanced resistance to serum degradation in comparison to the 
parent linear BimBH3, residues located at the C-terminus of BimSAHBA are less protected by 
stapling and more vulnerable to cleavage by proteases (Figure S7). Peptide 3 was the most 
selective for A1/Mcl-1, but it did not target A1 in cells as well as 5, suggesting an inferior 
capacity to reach the cytosol. The synthetic yield for 3 was also poorer, making this peptide less 
attractive for further investigation. 
 
 
Cycle 2 (µM) Bicycle 3 (µM) Bicycle 4 (µM)
50   10     5     1    0.1 50   10     5     1    0.1 50   10     5      1    0.1
Bicycle 5 (µM) Bicycle 6 (µM) Bicycle 7 (µM)
50   10     5     1    0.1 50   10     5     1    0.1 50   10     5      1    0.1
A1
GAPDH
A1
GAPDH
 17	
Non-covalent A1/Mcl-1 dual inhibitor. Having optimised the series to compound 5 as 
the best covalent ligand for inhibiting A1 and Mcl-1 proteins, we removed the acrylamide 
electrophile and replaced it with the isosteric propionamide to produce analogue 7 (Figure 7A). 
Compound 7 was a reversible non-covalent inhibitor with high affinity for A1 and Mcl-1, 
suggesting that the other changes to the peptide had compensated for the effect of an electrophile 
resulting in high recognition of the A1 and Mcl-1 binding pocket (Figure 7B and Table S1). 
Changing the acrylamide (5) to propionamide (7) did not affect hydrophobicity or structure, as 
reflected by identical HPLC retention times, CD measured helicity, and similar binding to other 
Bcl2 proteins (Figure 7B). To potentially improve selectivity for Mcl-1/A1, we replaced Glu 
with Leu at position 6, a change previously reported to weaken interaction of BimBH3 with Bcl-
2, Bcl-w or Bcl-xL proteins. Fluorescence polarization competitive binding measurements 
demonstrated that bicycle 8 (Figure 7A) had substantially reduced affinity for Bcl-w and Bcl-xL, 
while maintaining affinity at low nanomolar concentrations for Mcl-1 and A1 (Figure 7B). A 
fluorescein-labelled analogue of bicycle 8, peptide 9 (Figure 7A), was synthesized to measure 
direct binding to the proteins and confirm this selectivity. Indeed, 9 did have affinity at low 
nanomolar concentrations for both A1 and Mcl-1, but with 50-1000 fold selectivity over other 
Bcl2 proteins (Figure 7C). Peptide 9 was also examined for cell permeation using flow 
cytometry, establishing that construct 8 was cell permeable (Figure 8A). Additionally, western 
blot analysis of an acrylamide derivative of 8, peptide 10, revealed similar covalent bonding as 
bicycle 5 to intracellular A1 (Figure S8). 
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Figure 7. A) Structure of bicyclic peptides 7, 8 and 9 with no electrophile.  X’= Dap-N-
propionamide. B) Comparison of Ki values (nM) for binding of 7 and 8 to five anti-apoptotic 
Bcl2 proteins. Ki values below the dotted line were < 1 nM. C) Direct FP assays displaying 
binding affinity of the FITC-derived peptide 9 (10 nM) to the Bcl2 proteins. The Kd values 
determined from the binding curves for each Bcl2 protein are listed in the table.  
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 To evaluate the ability to induce apoptosis of human melanoma cells, we incubated 
bicycle 8 with SKMel-28 melanoma cells, which express Mcl-1 and A1 and are reportedly 
sensitive to Mcl-1/A1 protein silencing.5-8 Using an MTT assay, we observed that bicycle 8 
reduced SKMel28 cell viability in a dose-dependent manner (IC50 8.8 µM) after 48 h incubation 
(Figure 8B), more potently than the parent BimSAHBA (IC50 15.7 µM, Figure S9). The observed 
cell death was not caused by nonspecific cytotoxicity via cell membrane lysis, as an LDH release 
assay confirmed no cell lysis even in the presence of 50 µM peptide (Figure 8C). To correlate the 
observed decrease in cancer cell viability with intracellular A1/Mcl-1 targeting, we analyzed the 
association of pro-survival proteins A1 and Mcl-1 with pro-apoptotic protein Bim in SKMel28 
cells, using anti-Bim immunoprecipation (IP). As depicted in Figure 8D, bicycle 8 was capable 
of blocking the interaction of either A1 or Mcl-1 with endogenous Bim.  Next we evaluated the 
capacity of bicycle 8 to sensitize SKMel28 cells to apoptosis induced by chemotherapeutic 
drugs. As shown in Figure 8E, peptide 8 exhibited a synergistic effect with the drug etoposide, 
with the combination of both agents enhancing cell death. 
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Figure 8. Activity of bicyclic helix 8 (no electrophile) in SKMel28 melanoma cells. A) Flow 
cytometry shows cell uptake of bicyclic helix 9 (FITC-8) at similar concentrations as 21mer 
fluorescein-labelled 1 (FITC-1). Linear FITC-BIM was a control with negligible cell 
permeability. B) Cell viability after incubation with 8 for 48 h. C) LDH release after incubation 
of SKMel28 cells with 8. D) Bicycle 8 blocked binding of endogeneous pro-apoptotic Bim to 
Mcl-1 and A1. SKMel28 cells were treated with 8 (30 µM) for 24 h and immunoprecipitation 
were performed for Bim. Cell lysate and eluted immunoprecipitated (IP) proteins from beads 
were western blotted for Mcl-1 and A1 proteins. E) Cell viability after incubation with etoposide 
(black) or 8 (green) or both (blue) for 48 h. 
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In conclusion, we have developed short helical bicyclic Bim-derived peptides as potent 
dual inhibitors of Bcl2A1 and Mcl-1, with selectivity over other Bcl-2 family proteins. These 
compounds were shown to penetrate lymphoma and melanoma cells expressing Bcl2A1 and 
Mcl-1. One of these compounds, optimized for Bcl2A1 and Mcl-1 binding, was shown to induce 
apoptosis of human SKMel28 melanoma cells. A series of chemical changes were made to the 
26-residue BimBH3 peptide, which indiscriminately binds all Bcl2 proteins. The modifications 
were: (i) truncation to a 14-residue sequence by removing multiple N- and C- terminal residues; 
(ii) strategic incorporation of two helix-inducing constraints, one C-terminal KD lactam bridge to 
induce stronger α-helicity and one N-terminal hydrocarbon crosslink to aid cell penetration; and 
(iii) a Glu-to-Leu substitution to increase A1/Mcl-1 selectivity and hydrophobicity and cell 
uptake. These modifications led to helical bicyclic peptide 8, a novel cell-permeable A1/Mcl-1 
inhibitor with higher resistance to proteolytic degradation and more binding selectivity over 
other Bcl2 family proteins than BimBH3 or BimSAHBA (Figure 7). These compounds add to our 
growing library of novel bicyclic peptidomimetics.30,31 
 We have previously shown that a peptide helix with an acrylamide warhead can bond 
covalently and selectively to a specific cysteine in the protein A1.22 This could be a valuable 
approach to silencing proteins and prolonging the in vivo action of peptide drugs in particular, 
since high clearance rates usually shorten the duration of action of peptides. In this paper we 
have instead focused on using a small electrophile appendage as a tool to permit observation of 
an intracellular covalent peptide-A1 adduct in live cells, which is otherwise not detectable. We 
did detect intracellular targeting of the electrophilic peptides to mitochondrial A1, assisting 
optimization of the peptide sequence for target selectivity and cell activity. This approach is 
different from conventional tagging with bulky hydrophobic fluorophores that can distort 
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assessments of cell permeability. First, the acrylamide is small and less likely to interfere with 
ligand structure and chemical properties than bulky hydrophobic fluorophores. Second, it shows 
whether the ligand is capable of reaching its cytosolic target, without being influenced by 
hydrophobic fluorophores. Third, the use of covalent bonding electrophiles aids optimization of 
other ligand components for enhanced affinity for the target protein but, once optimized, can 
potentially be removed. For example, it was traditional for many years to use an electrophile in 
serine protease inhibitors to confer high potency but, once other components of the covalent 
ligand were optimized, sometimes the electrophile could be removed to leave highly potent non-
covalent inhibitors.31 Similarly we were able to derive bicyclic helical peptide 8, without 
electrophile from inhibitor 5 with electrophile. Due to their unique Mcl-1/A1 selectivity, bicyclic 
helical compounds 5, 7 and 8 could potentially be useful mechanistic tools for investigating the 
biological implications of Mcl-1 and A1 dual inhibition in vivo and enable further development 
of a peptide drug to induce apoptosis in cancer cells expressing those proteins.  
In a more general context, the combination of shortening helical peptides using back-to-
back cyclisation constraints, together with incorporating an electrophile for covalent binding, 
represents a powerful new approach to targeting protein-protein interaction interfaces. It 
effectively enables selective and irreversible silencing of a protein, the selectivity being perhaps 
surprising given that covalent inhibitors have long been maligned for non-selective protein 
interactions. The key to selectivity here is the helix motif, which directs the ligand specifically to 
the Bcl2A1 binding site, whereupon a secondary interaction with Cys55 anchors the ligand 
irreversibly to the protein. As the helix is shortened there is a risk that the initial targeting 
selectivity could be diminished, but it is worth noting that the majority of protein-protein 
interactions involving a helix in biology only use 1-4 helical turns.30d Therefore, the bicyclic 
approach shown here may be suitable for recapitulating most protein-helix interactions in 
biology, with or without a pendant electrophile for enhanced affinity, as long as the helix-
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inducing constraints do not negatively impact on binding to the protein target. The inherent 
ability of the bicyclic helix alone to bind with high affinity to a protein target, without the need 
for an electrophile, is also demonstrated here for Mcl-1. This example reveals the promise of two 
adjacent helix constraints30c,d for pre-organizing even a short peptide sequence into a receptor-
binding helical conformation.32 
 
 
 
EXPERIMENTAL SECTION 
 
Synthesis. Compounds 1 and FITC-1 were synthesized and characterized as previously 
described.22 Synthetic schemes illustrating the stepwise synthesis of compounds are given in 
Scheme 1 (compound 5) and Figure S1 (compound 2-4, 6-10) and compound characterization is 
reported in Supporting Information.  
 
SPPS: assembly of the linear peptide sequence. Peptides were assembled on solid support 
using Fmoc-based chemistry on a peptide synthesizer (Symphony, Protein Technologies) 
utilizing a low loading Rink Amide MBHA resin.22,26 Standard Fmoc-protected amino acids 
were employed for the synthesis, except: the unusual amino acid Fmoc-(S)-2-(4’-
pentenyl)alanine (Fmoc-S5-OH) was used for the incorporation of the two hydrocarbon handles 
at positions 1 and 5 and/or positions 9 and 13; the Mtt-protected lysine building block Fmoc-
Lys(Mtt)-OH and the OPip-protected aspartic acid Fmoc-Asp(OPip) were used for the 
incorporation of orthogonally protected Lys/Asp pair at positions 1 and 5 and/or positions 9 and 
13; Fmoc-Dap(Mtt)-OH or Fmoc-Dap(Boc)-OH was coupled at the position 2 when appropriate. 
Usually, 4 equiv. of Fmoc-protected amino acid, 4 equiv. of HCTU and 4 equiv. of DIPEA were 
used in 2 x 30 min coupling cycles. Fmoc deprotection was achieved by treatment with 1:2 
piperidine:DMF for 2 × 3 min. For N-terminal acetylated peptides, the N-terminus was 
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acetylated with Ac2O:DIPEA (1 M:0.4 M) in DMF for 2 x 5 min. For peptide 9 containing FITC 
at the N-terminus, the peptide assembly continued to incorporate the N-terminal residue Fmoc-
βAla-OH prior RCM. FITC was incorporated to the N-terminus by treating the free amine resin 
with FITC (2 equiv) and DIPEA (4 equiv) in DMF overnight.  
 
On-resin ring closing metathesis (RCM).25 Prior to RCM, the resin was washed with DCM and 
dried under high vacuum overnight. The dry resin was then placed in the synthesizer apparatus 
and swollen in dry DCE under N2 stream for 10 min and drained. The RCM reaction was 
performed by treating the resin with a 10 mM solution of Grubbs catalyst 1st generation in dry 
DCE (2 mL per 50 µmol resin) under N2 bubbling for 2h. The catalyst solution was drained and a 
fresh 10 mM Grubbs catalyst solution was added to the resin and reacted for 2h. After that, the 
resin was washed with DCM and DMF.  
 
On-resin lactam crosslinking. The resin was washed with DCM and treated repeatedly with 2% 
TFA in DCM (10 x 1 min). After washing with DMF, a solution of PyBOP (4 equiv) and DIPEA 
(8 equiv) in DMF was added to the resin. Full conversion to the side-chain crosslinked lactam 
was monitored by the ninhydrin test (usually 4-6 h). After completion, resin was washed with 
DMF. 
 
On-resin incorporation of the acrylamide or propionamide group to Dap2. After final 
assembly of the mono- or bis-stapled peptide, the resin was washed with DCM and treated 
repeatedly with a solution of 2% TFA in DCM (10 x 1 min). After washing with DCM and 
DMF, the resin was treated with 5% DIPEA in DMF then washed with DMF. After that, a 
solution of the acid (acrylic acid or propiolic acid; 4 equiv), HATU (4 equiv) and DIPEA (4 
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equiv) in DMF was added to the resin and the reaction was agitated for 15 min. Finally, the resin 
was washed with DMF and DCM, dried under vacuum and submitted to cleavage. 
 
Cleavage from solid support and peptide purification. Peptides were cleaved from the resin 
by treatment with TFA:TIS:H2O (95:2.5:2.5) for 2 h. The crude peptides were precipitated and 
washed with cold Et2O, redissolved in 50% acetonitrile/0.05% TFA in water and lyophilized. 
Peptides were purified by RP-HPLC using a Phenomenex Luna C18 column eluting at a flow 
rate of 20 mL/min and a gradient of 20 to 70% buffer B (90% CH3CN/10% H2O/0.1% TFA in 
buffer A, 0.1% TFA in water) over 30 min. Peptides were isolated to purity > 95% as determined 
by UPLC and RP-HPLC analysis. 
 
Off-resin incorporation of the acrylamide group. After cleavage from resin, the resulting 
freeze-dried crude peptide was combined with a solution of the acid (acrylic acid; 1.2 equiv), 
HATU (1.2 equiv) and DIPEA (2.4 equiv) in DMF and the reaction was agitated for 30 min. 
After that, the reaction was quenched by addition of aqueous TFA and the resulting solution 
directly injected into the RP-HPLC system for purification (as described above) to give the pure 
final peptide.  
 
Analytical methods. Purity and identification of the peptides was evaluated by analytical RP-
HPLC and UPLC-MS methods. Analytical RP-HPLC was performed on an Agilent system, 
using a Phenomenex Luna C18 5 um (250 x 4.60 mm) column eluting at a flow rate of 1 mL/min 
and a gradient of 30 to 100 % buffer B (90% CH3CN/10% H2O/0.1% TFA in buffer A, 0.1% 
TFA in water) over 20 min (Figure S10). UPLC-MS was performed on Shimadzu Nexre UPLC 
system connected to LCMS-2020 single quadrupole mass spectrometer using an Agilent Zorbax 
R-ODS III column a gradient of 20 to 80 % buffer B (90% CH3CN/10% H2O/0.1% formic acid 
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in buffer A, 0.1% formic acid in water) over 6 min (Figures S11 and S12). High-resolution mass 
spectroscopy was carried out on an Applied Biosystems QSTAR Electrospray quadrupole-
quadrupole Elite time-of-flight mass spectrometer (Table S2).  
 
Peptide concentration and storage. The concentration of pure peptide samples was determined 
by NMR in 50% acetonitrile-d3 in water (1-5 mM) using Pulcon method.33 Samples were then 
freeze-dried and redissolved in DMSO (for stock solutions of 10 mM concentration) and stored 
at -200C. 
 
Proteins for in vitro binding assays. Bcl-w (ab151806), Bcl-xL (ab 180062), Bcl-2 (ab 84209) 
and Mcl-1 (ab131682) were purchased from Abcam. A1 (C103) was purchased from 
Novoprotein. The commercial sample was diluted to a concentration of 10 µM protein in buffer 
containing 50 mM Tris, 150mM NaCl, 1 mM EDTA and 10 mM TCEP, pH 7.2 and incubated in 
this TCEP buffer for at least 30 min on an ice bed (max. 60 min) prior to the binding assays. 
 
Fluorescence polarization (FP) binding assays. FP measurements were performed at room 
temperature using a PHERAstar FS plate reader equipped with fluorescein excitation (490 nm) 
and emission (520 nm) filters. Samples were placed on a 384-well black plate (Corning) with a 
total volume in each well of 20 µL with a running buffer containing 50 mM Tris, 150mM NaCl, 
1 mM EDTA, 1 mM TCEP, 0.005% Tween-20, pH 7.2. Direct binding of FBid to Bcl2 
proteins. FBid (5-20 nM, FITC-βAla-DIIRNIARHLAQVGDSMDRSI-NH2)22 was incubated 
with different concentrations of each Bcl2 protein (two-fold dilutions ranging from 1 to 1000 
nM) in running buffer. FP was measured after 1h incubation and Kd values for Bcl2 protein 
binding to FBid were determined by nonlinear regression analysis using Prism software 7.0 
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(GraphPad). The experiment was repeated three times. Results (FBid concentration used/found 
Kd value): A1 (5/5.8 nM), Mcl-1 (20/105 nM), Bcl-w (10/32.3 nM), Bcl-xL (10/9.7 nM) and 
Bcl-2 (10/19.8 nM).  
 
Competition assays against FBid/Bcl2 protein complex. The IC80 value calculated from the 
direct binding assay was used to determine the protein concentration to be applied in the 
competition assays (FBid/protein concentration used: A1 (5/15 nM), Mcl-1 (20/200 nM), Bcl-w 
(10/65 nM), Bcl-xL (10/60 nM) and Bcl-2 (10/50 nM)). In general, the Bcl2 protein was 
preincubated with FBid for 30 min in running buffer and combined with a serial dilution of the 
peptide (ranging from 40 µM to 0.1 nM). After 2 h incubation, fluorescence anisotropy was 
measured and normalized accordingly to the signals recorded for free FBid (set as 100%) and 
protein/FBid complex alone (set as 0%). IC50 values were determined by nonlinear regression 
analysis using Prism software 7.0. Ki values (Table S1) were calculated from the observed 
competitive IC50 values after 2 h incubation, the Kd of FBid/Bcl2 protein interaction and known 
concentrations of labelled peptide and protein using a formula described34 and available 
online.34b Each experiment was repeated at least three times.  
 
Direct binding of peptide 9 to Bcl2 proteins. Peptide 9 was incubated with different 
concentrations of each Bcl2 protein (two-fold dilutions starting from 2000 nM) in running buffer. 
FP was measured after 1 h incubation and Kd values for Bcl2 binding to FBid were determined 
by nonlinear regression analysis using Prism software 7.0 (GraphPad). The experiment was 
repeated three times. 
 
Kinetic data for covalent binding of peptides 1-6 to A1. A1 (15 nM) was preincubated with 
FBid (5 nM) for 30 min in running buffer and combined with a serial dilution of the peptide (at 
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500, 250, 125, 62.5, 31.2, 15.6, 7.8 and 3.9 nM concentration). After 15, 30, 60, 90 and 120 min 
incubation, FP was measured and normalized accordingly to the signals recorded for free FBid 
(set as 100%) and A1/FBid complex alone (set as 0%). The covalent binding was analysed 
following the methodology described in reference 29. The change in normalized polarization 
over time (t) was fitted into the equation: normalized polarization = 100*(1 - exp(-kobs*t)) and 
kobs values for each peptide concentration were determined by nonlinear regression analysis (one 
phase decay) using Prism software 7.0. The calculated kobs values were then used to determine 
the parameters kinact and KI by plotting the curve: kobs = kinact*[peptide]/(KI + [peptide]) using 
Prism software (nonlinear regression, hyperbola equation). Each experiment was repeated at 
least three times. 
 
SDS-PAGE electrophoresis. A1 and peptides were combined in buffer (50 mM Tris, 150mM 
NaCl, 1 mM EDTA, 2 mM TCEP, 0.005% Tween-20, pH 7.2) to a final concentration of 1 µM 
A1 and 10 µM peptide in a total of 20 µL reaction volume. After incubation at room temperature 
for 2 h, the reaction was immediately submitted to SDS-PAGE analysis as described.22  
 
In gel trypsin digestion. Using SDS-PAGE from Figure 5A, the gel band corresponding to the 
conjugate formed after reacting A1 with peptide 5 was removed and digested with trypsin 
following a procedure described.22 The digest was redissolved in 0.5 % formic acid / 50 % 
acetonitrile and analyzed by LC-MS on a Shimadzu Nexera uHPLC (Japan) coupled to a Triple 
TOF 5600 mass spectrometer (ABSCIEX, Canada) equipped with a duo electrospray ion 
source.22 The data was acquired and processed using Analyst TF 1.6 software (ABSCIEX, 
Canada). Digested A1 was identified by database searching using ProteinPilot v4 (ABSCIEX) 
against the UniProt_Sprot_20110925 database. MS-MS spectrum of digested protein was 
scanned for the inserted peptide sequence ELR sequence from 5 and also for the A1 fragment 
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sequence LDNVNVVSLDTAR (Figure 4C and S4). A single protein fragment was found and 
further characterized as the expected conjugated peptide-protein fragment (Figure 5C and S5). 
 
Stability in rat plasma. Peptides BIM, 1, 5 and 8 (5 µL of 1 mM stock solution, dissolved in 5 
µL water) were incubated with 490 µL fresh rat plasma over 24 h at 37 °C. During this time, 40 
µL aliquots were taken at 0, 0.33, 2, 5, 11 and 22 h and quenched with 120 µL 90% acetonitrile, 
cooled on ice for 5 min, placed in a centrifuge and spun at 17 g for 10 min. Then, 120 µL of the 
clear solution was transferred into a vial and analyzed by LC-MS. The rate of peptide 
deterioration was quantified based on intensity of intact peptide mass peak over time. The 
experiment was repeated three times for each peptide (Figure S6). 
 
Cells. U937 cells were cultured in RPMI supplemented with 10% FBS, 10 U/mL penicillin, 10 
U/mL streptomycin, 2 mM GlutaMax, 2 mM NEAA and 1 mM HEPES. SKMel28 cells were 
cultured in DMEM supplemented with 10% FBS, 10 U/mL penicillin and 10 U/mL 
streptomycin.  
 
Covalent binding in live U937 cells. U937 cells were plated at a density of 5 x 105 cells and 
treated with peptides in the presence of 5% FBS for 24 h. After incubation, cells were washed 
and lysed with Cell Lysis Buffer supplemented with Protease/Phosphatase Inhibitor Cocktail 
(Cell Signaling Technology). Samples were reduced at 70°C for 5 min followed by western blot 
analysis using anti-A1 (Cell Signaling Technology) and anti-GAPDH (Sigma Aldrich). 
 
Flow cytometry. SKMel28 cells were treated with 10 µM fluorescein-labeled peptides for 4 h at 
37 °C followed by washing and quenching by trypan blue to remove non-specific binding. Cells 
were then analysed by flow cytometry on a Gallios Flow Cytometer (Becton Dickson) and MFI 
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data were analyzed using FlowJo (Tree Star Inc). Significant differences were determined using 
2-way ANOVA using FITC-BIM as control. P value < 0.0001 ****, 0.001 ***, 0.01 **. 
 
Cell viability and LDH release assay. SKMel28 cells were plated at a density of 4 x 104/mL 
and allowed to adhere overnight. For LDH release assay, peptides were incubated at indicated 
concentration in serum-free DMEM for 30 min. LDH were measured using CytoTox Non-
Radioactive Cytotoxic Assay (Promega) according to manufacturer’s instruction. For MTT 
viability assay, 8 was incubated with or without etoposide at indicated concentration in serum-
free DMEM for 48 h. After incubation, MTT (Invitrogen) was then added to the cells at 1 
mg/mL for 90 min at 37 °C. The resulting formazan were dissolved in isopropanol and measured 
using PHERAstar (BMG Labtech) at 570 nm.  
 
Coimmunoprecipitation. SKMel28 cells were treated with 8 (30 µM) for 24 h at 37°C, then 
lysed with Cell Lysis Buffer supplemented with Protease/Phosphatase Inhibitor Cocktail (Cell 
Signaling Technology). Immunoprecipitation was performed was per manufacturer’s 
instructions. Briefly, cell lysate was pre-cleared with protein A magnetic beads (Cell Signaling 
Technology) then incubated overnight with anti-Bim (Cell Signaling Technology). Protein A 
magnetic beads were then added to form antibody-protein A complex. Unbound proteins were 
washed in lysis buffer and subjected to boiling to elute proteins. Eluted proteins were used for 
western blot analysis using anti-Mcl-1 and anti-A1 (Cell Signaling Technology) using iBlot and 
iBind systems (Invitrogen). 
 
Data analysis. Data were plotted and analyzed using GraphPad Prism 7 for Mac OSX. All 
values of independent parameters are mean ± SEM of at least three independent experiments. P 
value < 0.0001 ****, 0.001 ***, 0.01 **. 
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